Maravai LifeSciences Holdings Inc
NASDAQ:MRVI

Watchlist Manager
Maravai LifeSciences Holdings Inc Logo
Maravai LifeSciences Holdings Inc
NASDAQ:MRVI
Watchlist
Price: 5.33 USD 3.9% Market Closed
Market Cap: 1.3B USD
Have any thoughts about
Maravai LifeSciences Holdings Inc?
Write Note

Maravai LifeSciences Holdings Inc
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Maravai LifeSciences Holdings Inc
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Maravai LifeSciences Holdings Inc
NASDAQ:MRVI
Accounts Payable
$10.7m
CAGR 3-Years
9%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Accounts Payable
$2.6B
CAGR 3-Years
4%
CAGR 5-Years
9%
CAGR 10-Years
12%
Danaher Corp
NYSE:DHR
Accounts Payable
$1.6B
CAGR 3-Years
-9%
CAGR 5-Years
0%
CAGR 10-Years
-1%
Mettler-Toledo International Inc
NYSE:MTD
Accounts Payable
$202.9m
CAGR 3-Years
-3%
CAGR 5-Years
6%
CAGR 10-Years
5%
Agilent Technologies Inc
NYSE:A
Accounts Payable
$540m
CAGR 3-Years
7%
CAGR 5-Years
9%
CAGR 10-Years
6%
IQVIA Holdings Inc
NYSE:IQV
Accounts Payable
$3.4B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
15%
No Stocks Found

Maravai LifeSciences Holdings Inc
Glance View

Market Cap
1.3B USD
Industry
Life Sciences Tools & Services

Maravai LifeSciences Holdings Inc. operates in the niche yet burgeoning market of life sciences, where its business revolves around the creation and supply of essential products and services for biotechnology workflows. Founded in 2014 and headquartered in San Diego, California, Maravai specializes in providing key components for the development of diagnostics and therapeutics. A significant portion of its revenue is driven by its business unit, TriLink BioTechnologies, which is instrumental in the synthesis of nucleic acids, notably mRNA and modified nucleotides – critical for the development of mRNA vaccines like those used in combating COVID-19. This has positioned Maravai as a crucial player during the pandemic, spotlighting its capability to provide high-quality inputs that support leading-edge scientific innovations. The company’s financial engine is powered by its diversified product offerings across three main segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. Beyond just supplying raw materials, Maravai elevates its contributions by ensuring these components meet rigorous quality standards necessary for clinical applications. The robust demand for both biopharmaceutical innovation and bioprotection has allowed Maravai to capitalize on trends such as personalized medicine and gene therapy. By navigating these influential currents in the biotechnology space, Maravai LifeSciences not only gains from direct sales of its products but also cultivates long-standing partnerships across pharmaceutical and research organizations, underscoring its integral role in the ongoing evolution of life sciences.

MRVI Intrinsic Value
2.89 USD
Overvaluation 46%
Intrinsic Value
Price

See Also

What is Maravai LifeSciences Holdings Inc's Accounts Payable?
Accounts Payable
10.7m USD

Based on the financial report for Dec 31, 2023, Maravai LifeSciences Holdings Inc's Accounts Payable amounts to 10.7m USD.

What is Maravai LifeSciences Holdings Inc's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
24%

Over the last year, the Accounts Payable growth was 79%. The average annual Accounts Payable growth rates for Maravai LifeSciences Holdings Inc have been 9% over the past three years , 24% over the past five years .

Back to Top